Cardiorenal Syndrome: A Clinical and Trial Perspective
Sponsored by: Covance
- Cardiorenal Syndome
- Cardiorenal Outcomes In Recent Sglt 2 Inhibitor Trials
Date: 10 September
Days to go: 24
Time: 4PM London/11AM New York
Cardiac disease is often accompanied by renal disease given the highly connected, bidirectional interplay between the heart and the kidneys. Damage or dysfunction in one organ can cause the impairment in the other and these interconnected disorders are considered part of “cardiorenal syndrome” (CRS). Since CRS was first classified into five subtypes by Ronco and McCullough et al. more than 10 years ago, research has continued to explore and improve diagnostic and treatment strategies in this multidisciplinary area.
Given the overlap of dysfunction presented with this systemic disease, our industry faces many challenges when designing and conducting a trial for a cardiorenal treatment. Drug development sponsors need to understand how to address the connections between cardiovascular and kidney diseases and consider the cardiorenal endpoints that will translate to clinically meaningful outcomes.
This webinar provides a comprehensive overview of cardiorenal syndrome, risk factors and the use of the clinical laboratory for supporting risk prediction, detection and disease management. The presentation will include a discussion on: CRS type 1, the development of acute kidney injury (AKI) and dysfunction in the patient with acute cardiac illness; role of the novel anti-diabetic agents and cardiorenal outcomes and emerging data from recent diabetic kidney disease trials with cardiorenal outcomes to support more informed design and conduct of trials across wide range of recent cardiorenal studies.
Cheerag Shirodaria, BSc, MBBS, MD, FRCP, MBA,
Vice President & General Manager, Medical Device & Diagnostics, Cardiovascular GlobalTherapeutic Area Head
Dr. Shirodaria leads the cardiovascular physician group at Covance and is also head of the Medical Device & Diagnostics business unit.
He has worked in academic and clinical practice for more than 20 years and is an interventional cardiologist by training. Dr. Shirodaria is also an expert in cardiac imaging; he completed his doctoral thesis at the University of Oxford under the supervision of Professor Stefan Neubauer on the development of novel imaging parameters for the assessment of cardiovascular disease using cardiac MRI, in particular heart failure imaging. He is co-director of the cardiac computed tomography (CT) imaging program in Oxford, where he remains on the faculty. He has extensive experience in designing and leading cardiometabolic trials, including convening their Strategic Advisory Boards.
Dr. Shirodaria leads the Covance Academic Research Organisation (ARO) Governance Group and oversees ARO’s relationship with Covance from a medical perspective. He is also a member of the Steering Committee for a number of cardiovascular outcomes trials.
Dr. Shirodaria earned his medical degree at St. Bartholomew’s and the Royal London School of Medicine and Dentistry at the University of London. He also obtained a Bachelor of Science degree in Pharmacology from University College, London as well as a master’s degree in Business Administration (MBA) from the London Business School. He received his Doctorate of Medicine (MD) at the University of Oxford where he remains on the faculty.
Peter A. McCullough, MD, MPH, FACP, FACC, FCCP, FAHA, FNKF, FNLA, FCRSA,
Founder and current president, Cardio Renal Society of AmericaVice Chief of Medicine, Baylor University Medical Center, Principal Faculty, Texas A & M
Dr. McCullough is an internationally recognized authority on the role of CKD as a cardiovascular-risk state with more than 1000 publications and 500 citations in the National Library of Medicine. His works include the chapter “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook.
Dr. McCullough has led observational studies and randomized trials of therapies for acute kidney injury, hypertension, acute coronary syndromes, heart failure and cardiorenal syndromes, as well as chaired and participated on 20 data safety monitoring committees for large randomized trials. He advised sponsors and the FDA resulting in approval of 17 new drugs and 3 novel in vitro diagnostic tests used today around the world.
He serves on the editorial boards of multiple specialty journals, made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency and the U.S. Congressional Oversight Panel.
Janani Rangaswami, MD, FACP, FCRS,
Clinical Associate Professor, Sidney Kimmel College of Thomas Jefferson University, Associate Program Director, Department of Medicine, Einstein Medical Center, Philadelphia, PA.
Janani Rangaswami completed medical school at MGR Medical University, Chennai, India where she graduated as the valedictorian of her class with several awards of distinction. She then went on to complete her residency and chief residency in Internal Medicine at Albert Einstein Medical Center, Philadelphia and a fellowship in Nephrology at Weill Cornell Medical Center, NY. She maintains an active clinical and research practice in cardiorenal medicine at Einstein and serves as the associate program director for the Internal Medicine residency program, in addition to directing the Residency Research Track. She is clinical associate professor at Thomas Jefferson University, and has won several awards from residents and fellows for clinical teaching and mentorship. She is the president-elect for the Cardiorenal Society of America. She vice-chaired the first American Heart Association Scientific Statement on Cardiorenal Syndrome (2019) and is chair of the Cardiovascular Work Group of the Kidney/Pancreas section of the American Society of Transplantation. In addition to her interests in cardiorenal medicine, she also serves on the leadership of Women in Medicine for the American College of Physicians, with ongoing efforts towards mentorship and career support for women physicians. She has spoken and presented work at several national specialty meetings in the cardiorenal space.
Key Learning Objectives
- Gain a stronger understanding of CRS and risk factors
- Hear how a clinical laboratory can predict risk, detect and help manage CRS
- Learn about type 1 CRS and the clinical implications for acute heart failure
- Review emerging data from recent diabetic kidney disease trials with cardiorenal outcomes
- Medical Affairs
- Project Management
- Regulatory Specialist
- Clinical Operations
- Commercial and Sales
- Chief Medical Officer
- Chief Development Officer
- Medical Director
- Operational Director
- Clinical Development Director
- Clinical Development Manager
- Procurement Manager